Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats

Shunsuke Fujita, Soichiro Ushio, Nana Ozawa, Ken Masuguchi, Takehiro Kawashiri, Ryozo Oishi, Nobuaki Egashira*

Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan

Abstract

Background

Oxaliplatin has widely been used as a key drug in the treatment of colorectal cancer; however, it causes peripheral neuropathy. Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, is an incretin mimetic secreted from ileal L cells, which is clinically used to treat type 2 diabetes mellitus. GLP-1 receptor agonists have been reported to exhibit neuroprotective effects on the central and peripheral nervous systems. In this study, we investigated the effects of exenatide on oxaliplatin-induced neuropathy in rats and cultured cells.

Methods

Oxaliplatin (4 mg/kg) was administered intravenously twice per week for 4 weeks, and mechanical allodynia was evaluated using the von Frey test in rats. Axonal degeneration was assessed by toluidine blue staining of sciatic nerves.

Results

Repeated administration of oxaliplatin caused mechanical allodynia from day 14 to 49. Although the co-administration of extended-release exenatide (100 μg/kg) could not inhibit the incidence of oxaliplatin-induced mechanical allodynia, it facilitated recovery from the oxaliplatin-induced neuropathy with reparation of axonal degeneration. Inhibition of neurite outgrowth was evaluated in cultured pheochromocytoma 12 (PC12) cells. Exenatide inhibited oxaliplatin-induced neurite degeneration, but did not affect oxaliplatin-induced cell injury in cultured PC12 cells. Additionally, extended-release exenatide had no effect on the anti-tumor activity of oxaliplatin in cultured murine colon adenocarcinoma 26 (C-26) cells or C-26 cell-implanted mice.

Conclusion

These results suggest that exenatide may be useful for treating peripheral neuropathy induced by oxaliplatin in colorectal cancer patients with type 2 diabetes.
Introduction

Oxaliplatin, a platinum-based chemotherapeutic agent, is a key drug widely used for treating colorectal cancer; however, it causes severe acute and chronic peripheral neuropathies. In the early phase after administration, the acute neuropathy occurs in 85 to 95% of all patients and they suffer from cold hyperesthesia [1]. It has been thought that the acute neuropathy is not due to morphological damage of the nerve [2] and is due to alternations of voltage-gated Ca$^{2+}$ and K$^+$ channels [3, 4]. Recently, transient receptor potential (TRP) melastatin (M) 8 and ankyrin (A) 1 channels have been reported to play an important role in the oxaliplatin-induced acute cold hypersensitivity in rodents [5, 6]. More recently, the voltage-gated Nav1.9 sodium channel has been reported to be associated with cold pain hypersensitivity induced by oxaliplatin [7]. After multiple cycles, patients develop chronic neuropathy, which is characterized by sensory and motor dysfunction [8]. This chronic neuropathy is dose limiting and often not only limits the patient’s activities of daily living, but also hinders long-term use of oxaliplatin-based chemotherapy [9]. Moreover, the chronic neuropathy takes at least 2 years after discontinuation of the drug to completely recover from the neuropathy in 10% of patients [10]. Thus, these neuropathies are a major clinical problem in oxaliplatin chemotherapy.

Oxaliplatin causes damage to cell bodies [11–13] and selective atrophy of subpopulations of dorsal root ganglion (DRG) neurons [14]. Recently, the activation of spinal astrocytes has been reported to be involved in the oxaliplatin-induced neuropathic pain [15–17]. N-Palmitoylethanolamine, the endogenous amide belongs to the family of fatty acid ethanolamides (FAEs), has been reported to modulate glial cells and exert antinociceptive effects on oxaliplatin-induced neuropathic pain in rats [18]. Furthermore, it has been reported that α7 nicotinic acetylcholine receptor (nAChR) subtype is involved in the oxaliplatin-induced neuropathy, and α7 nAChR-dependent modulation of glial functions improves the pain-related behavior [19]. Oxaliplatin is metabolized to oxalate and dichloro (1,2-diaminocyclohexane) platinum [Pt(dach)Cl$_2$] [20]. We previously reported that repeated administration of oxaliplatin induced cold allodynia from day 5 and mechanical allodynia from day 15 in rats [21]. Oxaliplatin causes degeneration of myelinated fibers in the rat sciatic nerve and inhibits neurite outgrowth in cultured pheochromocytoma 12 (PC12) and rat DRG cells [21]. We also demonstrated the involvement of Pt(dach)Cl$_2$ in mechanical allodynia but not cold allodynia [22]. Moreover, we showed that this mechanical allodynia is characterized by increased expression of the NR2B-containing N-methyl-D-aspartate (NMDA) receptor and enhanced calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylation in the spinal cord [23, 24]. Most recently, we indicated that oxaliplatin induces hypomyelination and reduces expression of neuregulin 1, a myelination regulatory factor, in the rat sciatic nerve [25]. However, the mechanisms of oxaliplatin-induced peripheral neuropathy have yet to be elucidated fully and preventive strategies have not yet been established [26].

Glucagon-like peptide-1 (GLP-1) is secreted from ileal L cells and stimulates the pancreas to secrete insulin via GLP-1 receptors. Exenatide is a GLP-1 receptor agonist that is clinically used to treat type 2 diabetes. Recently, GLP-1 receptor agonists have been shown to prevent or improve diabetic neuropathy model [27–29], and nerve crush and pyridoxine-induced neuropathy models [30, 31]. GLP-1 receptor agonist has also been reported to prevent against mitochondrial apoptotic pathway induced by spinal cord injury in rats [32]. Moreover, GLP-1 and GLP-1 receptor agonists have been reported to show neurotrophic and neuroprotective properties [33–35]. However, the effects of GLP-1 receptor agonists on oxaliplatin-induced peripheral neuropathy have not been studied. In the present study, we examined the effects of exenatide on oxaliplatin-induced inhibition of neurite outgrowth in cultured PC12 cells and oxaliplatin-induced mechanical allodynia in rats.
**Materials and Methods**

**Animals**

Six-week-old male Sprague-Dawley rats weighing 200–250 g (Kyudo Co., Tosu, Japan) were used in the present study. Six-week-old male BALB/c mice weighing 21–23 g (CLEA Japan, Inc., Tokyo, Japan) were used for the in vivo tumor growth model. Animals were housed in groups of three to four per cage, with lights on from 07:00–19:00 h. Animals had free access to food and water in their home cages. All experiments were approved by the Experimental Animal Care and Use Committee of Kyushu University according to the National Institutes of Health guidelines (Permit Number: A27-011-0), and followed the International Association for the Study of Pain Committee for Research and Ethical Issues guidelines for animal research [36].

**Cell cultures**

PC12 cells and murine colon adenocarcinoma 26 (C-26) cells were obtained from Riken (Saitama, Japan). Cells were maintained in DMEM (MP Biomedicals Inc., Irvine, CA, USA) containing 2 mM L-glutamine, 10% (v/v) fetal bovine serum and 10% (v/v) horse serum in a humidified atmosphere containing 5% (v/v) CO₂ at 37°C.

**Drugs**

Oxaliplatin (Elplat™) was obtained from Yakult Co., Ltd. (Tokyo, Japan) and was dissolved in 5% (w/v) glucose solution. Exenatide (Byetta™) and extended-release exenatide (Bydureon™) were purchased from AstraZeneca, Inc. (London, UK) and were used for in vitro and in vivo studies, respectively. Oxaliplatin (4 mg/kg) or vehicle (5% (w/v) glucose solution) was injected intravenously (i.v.), twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Oxaliplatin was administrated at a volume of 1 mL/kg of body weight. Extended-release exenatide (100 μg/kg) was injected subcutaneously (s.c.), once per week for 9 weeks (days 1, 8, 15, 22, 29, 36, 43, 50, and 57). The doses of oxaliplatin and exenatide were chosen based on previous reports [21, 37].

**Cell viability assay of cultured PC12 and C-26 cells**

PC12 and C-26 cells were seeded at a density of 6 × 10⁴ cells/well in 24-well plates and were used for experiments on the following day. PC12 cells were incubated in serum-free medium with nerve growth factor-b, rat recombinant carrier free (NGF; 60 μM; Wako Pure Chemicals, Osaka, Japan) for 24 h followed by exposure to oxaliplatin (3 μM) and exenatide (3, 10, or 30 nM) for 24 h. C-26 cells were incubated in serum-free medium and exposed to oxaliplatin (70 μM) and exenatide for 24 h. The concentrations of these drugs were chosen based on previous reports [21, 38, 39]. In addition, the concentration of oxaliplatin in C-26 cells was determined by the preliminary study. This concentration (70 μM) is required to reduce tumor growth by about 30%. Cell viability was assessed by the reduction of 2-(2-methoxy-4-nitrophényl)-3-(4-nitrophényl)-5-(2,4-disulfophényl)-2H-tetrazolium monosodium salt (WST-8) to formazan by mitochondria. Briefly, after treatment with oxaliplatin and exenatide, cells were washed with phosphate-buffered saline (PBS). Cells were incubated with 210 μL serum-free medium and 10 μL of WST-8 assay solution (Cell Counting Kit-8; Dojindo Laboratory, Kumamoto, Japan) for 1 h at 37°C in humidified air supplemented with 5% (v/v) CO₂. The incubation medium was carefully removed and transferred to 96-well flat-bottom plastic plates (Nalge Nunc International, Rochester, NY, USA). The amount of formazan formed was
measured from the absorbance at 450 nm with a reference wavelength of 620 nm using a microplate reader (Sunrise; TECAN Group Ltd., Mannedorf, Switzerland).

Assessment of PC12 neurite outgrowth
PC12 cells differentiate in the presence of NGF, and have previously been used as a model of oxaliplatin-induced neurodegeneration in vitro [21]. PC12 cells were seeded at a density of 5 × 10^3 cells/cm² in 96-well plates (Falcon; Becton Dickinson Co., Ltd., NJ, USA) and were used for experiments on the third day. Cultured cells were exposed to oxaliplatin (3 μM) and exenatide (3, 10, or 30 nM) for 24 h. They were stained with Calcein-AM (1:1000, Dojindo Laboratory, Kumamoto, Japan) and Hoechst 33342 (1:1000, Dojindo Laboratory) at 37°C for 10 min. Cells were monitored using ImageXpress (Molecular Devices Japan, Tokyo, Japan) and the lengths of neurite (number of neurite: from 600 to 1000) were measured using MetaXpress (Molecular Devices Japan) three times repeatedly.

von Frey testing for mechanical allodynia
We investigated the effect of exenatide on mechanical allodynia using the von Frey test. This test was performed before the first drug administration (day 0) and on days 7, 14, 21, 28, 35, 42, 49, 56, and 63. Rats were placed in a clear plastic box (20 × 17 × 13 cm) with a wire mesh floor and allowed to habituate for 30 min prior to testing. Filaments (The Touch Test Sensory Evaluator Set; Linton Instrumentation, Norfolk, UK) in the range of 1–15 g bending force were applied to the mid-plantar skin of each hind paw six times, with each application held for 6 s. The paw withdrawal threshold was determined by a modified up-down method as previously described by Kawashiri et al. [21].

Assessment of sciatic axonal degeneration
On days 28, 42, and 63, sciatic nerves were harvested from rats anesthetized with sodium pentobarbital. Nerves were fixed in 2% (w/v) glutaraldehyde in 0.1 M phosphate buffer (pH 7.4, 4°C) for 4 h followed by washing with 0.1 M phosphate buffer. After 8% (w/v) sucrose-substitution, each sample was cut into 5 mm length and embedded in paraffin. Paraffin blocks were sliced into 3 μm section, and each section was stained with 0.05% toluidine blue. Four sections were examined per mouse. Sample sections were evaluated using light microscopy (BX51; Olympus Corp., Tokyo, Japan). Axon area was calculated by image analysis software (Image J 1.36; Wayne Rasband, National Institutes of Health, MD, USA) from approximately 3000 to 6000 axons per group.

Tumor growth analysis
C-26 cells (1.0 × 10^6 cells per mouse in 50 μL PBS) were implanted subcutaneously in the right paw of BALB/c mice. Six days after implantation of tumor cells, administration of drugs was started. Oxaliplatin (6 mg/kg, i.p. days 1, 2, 8, and 9) and extended-release exenatide (150 μg/kg, s.c. days 1 and 8) were injected respectively. The dose of oxaliplatin followed previous report [40], and the dose of exenatide was chosen based on a previous report [41]. The tumor volumes were measured on days 0, 4, 7, and 11, and calculated as follows: Volume (mm³) = π/6 × Thickness (mm) × Length (mm) × Width (mm).

Statistical analyses
Values are expressed as the mean ± standard error mean. The values were analyzed by the Student’s t-test, or one-way analysis of variance followed by the Tukey-Kramer test (StatView;
Abacus Concepts, Berkely, CA, USA) to determine differences among the groups. Cell viability data of cultured PC12 and C-26 cells and neurite outgrowth measurements of PC12 cells are expressed as percentages of the vehicle-treated group. A $P < 0.05$ was accepted as statistically significant.

**Results**

**Effect of exenatide on oxaliplatin-induced neurite degeneration in cultured PC12 cells**

Exposure to oxaliplatin (3 $\mu$M) for 24 h shortened the length of PC12 neurites (Fig 1). The exposure to exenatide (10 and 30 nM) significantly prevented the oxaliplatin-induced inhibition of neurite outgrowth (10 and 30 nM, $P < 0.01$ by the Tukey-Kramer test).

**Effect of exenatide on oxaliplatin-induced cell viability in cultured PC12 cells**

As shown in Fig 2, exposure to oxaliplatin (3 $\mu$M) for 24 h decreased cell viability in cultured PC12 cells ($P < 0.01$ by the Tukey-Kramer test). Co-exposure to exenatide (3, 10, or 30 nM) for 24 h had no effect on the oxaliplatin-induced decrease in cell viability.

![Fig 1. Effect of exenatide on oxaliplatin-induced neurite degeneration in cultured PC12 cells. Cultured PC12 cells were incubated with oxaliplatin (3 $\mu$M) for 24 h in the presence or absence of exenatide (3, 10, or 30 nM). (A) Photographs were originally magnified 800 ×. Scale bar = 100 $\mu$m. (B) Neurite length was measured using image analysis software (MetaXpress). Results are expressed as the mean ± standard error mean ($n = 3$). **$P < 0.01$ compared with control, ††$P < 0.01$ compared with oxaliplatin alone.](https://doi.org/10.1371/journal.pone.0141921.g001)
Effects of extended-release exenatide on incidence of mechanical allodynia and histological changes induced by oxaliplatin

Animals were injected twice weekly with oxaliplatin for 4 weeks and once weekly with extended-release exenatide for 4 weeks. Oxaliplatin (4 mg/kg, i.v., twice per week) significantly lowered the withdrawal threshold compared with the vehicle on days 14, 21, and 28 (P < 0.01 by the Tukey-Kramer test, Fig 3A). Co-administration of extended-release exenatide (100 μg/kg, s.c.) had no effect on the oxaliplatin-induced reduction in withdrawal threshold. Histological studies revealed atrophy of myelinated fibers in the rat sciatic nerve of oxaliplatin-treated animals and rats co-administered oxaliplatin and exenatide for 4 weeks (Fig 3B). The quantification analysis showed that oxaliplatin significantly decreased area of axon (P < 0.01 by the Tukey-Kramer test), and co-treatment with exenatide had no effect on the oxaliplatin-induced decrease in area of axon.

Effects of extended-release exenatide on recovery from mechanical allodynia and histological changes induced by oxaliplatin

Animals were injected twice weekly with oxaliplatin for 4 weeks and once weekly with extended-release exenatide for 9 weeks. Oxaliplatin treatment ceased on day 23, however exenatide treatment was continued for an additional 5 weeks. Co-administration of extended-release exenatide (100 μg/kg, s.c.) significantly relieved oxaliplatin-induced mechanical allodynia on day 42 (P < 0.01 by the Tukey-Kramer test, Fig 4A). On day 63, no behavioral abnormalities were observed in rats treated with oxaliplatin. On day 42, atrophy of the sciatic nerve was observed in oxaliplatin-treated rats, but no histological abnormalities were observed in the co-treatment with exenatide group (Fig 4B). The quantification analysis showed that oxaliplatin significantly decreased area of axon (P < 0.01 by the Tukey-Kramer test), and co-treatment with exenatide reversed the oxaliplatin-induced decrease in area of axon (P < 0.01 by the Tukey-Kramer test, Fig 4C). On day 63, histological changes were little observed in rats treated...
Fig 3. Effects of extended-release exenatide on incidence of mechanical allodynia and axonal degeneration induced by oxaliplatin. Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Extended-release exenatide (100 μg/kg) was administered s.c. once per week for 4 weeks. (A) The von Frey test was performed before the first drug administration (on day 0) and on days 7, 14, 21, and 28. Values are expressed as the mean ± standard error mean of five to six animals. (B) On day 28, the sciatic nerve was harvested, and samples were stained with toluidine blue. Images were captured at 800x magnification. Scale bar = 60 μm. (C) The area of axon was calculated by image analysis software (Image J 1.36) from approximately 3000 to 6000 axons per group. Values are expressed as the mean ± standard error mean of four animals. **P < 0.01 compared with vehicle.

doi:10.1371/journal.pone.0141921.g003
Fig 4. Effects of extended-release exenatide on recovery from mechanical allodynia and axonal degeneration induced by oxaliplatin. Oxaliplatin (4 mg/kg) was administered i.v. twice per week for 4 weeks (days 1, 2, 8, 9, 15, 16, 22, and 23). Extended-release exenatide (100 μg/kg) was administered s.c. once per week for 9 weeks (days 1, 8, 15, 22, 29, 36, 43, 50, and 57). Oxaliplatin treatment ceased on day 23, however exenatide treatment was continued for an additional 5 weeks. (A) The von Frey test was performed before the first drug administration (on day 0) and on days 35, 42, 49, 56, and 63. Values are expressed as the mean ± standard error mean of five to six animals. (B) On days 42 and 63, the sciatic nerve was harvested, and samples were stained with toluidine blue. Images were captured at 800× magnification. Scale bar = 60 μm. (C) The area of axon (number of axon: from 3000 to 6000/field) was
with oxaliplatin (Fig 4B), but the quantification analysis showed that co-treatment with exenatide reversed the oxaliplatin-induced decrease in area of axon ($P < 0.01$ by the Tukey-Kramer test, Fig 4C).

**Effect of exenatide on oxaliplatin-induced tumor cytotoxicity**

Exposure of cultured C-26 cells to oxaliplatin (70 μM) for 24 h significantly decreased tumor cell viability ($P < 0.01$ by the Tukey-Kramer test, Fig 5). Exenatide (3, 10 or 30 nM) had no effect on the oxaliplatin-induced decrease in cell viability.

**Effect of extended-release exenatide on the anti-tumor activity of oxaliplatin in tumor cell-implanted mice**

Oxaliplatin (6 mg/kg, i.p.) significantly inhibited the increase in tumor volume when compared with vehicle in tumor cell-implanted mice (day 4: $P < 0.05$, day 11: $P < 0.01$ by Tukey-Kramer test, Fig 6). Extended-release exenatide (150 μg/kg, s.c.) had no effect on the oxaliplatin-induced inhibition of tumor growth.

**Discussion**

In the present study, oxaliplatin caused mechanical allodynia from day 14, which gradually dissipated after the end of oxaliplatin administration, and these results are consistent with our previous report [21]. Clinically, it has been reported to take 2 or more years to completely recover from peripheral neuropathy after discontinuation of oxaliplatin in 10% of patients [10]. Although co-administration of exenatide could not inhibit the incidence of oxaliplatin-induced mechanical allodynia, it facilitated recovery from oxaliplatin-induced neuropathy.
Therefore, exenatide may be useful for the treatment of oxaliplatin-induced chronic peripheral neuropathy.

We also observed that oxaliplatin caused atrophy of myelinated fibers in the rat sciatic nerve on day 28. However, co-administration of exenatide had no effect on these changes, suggesting that exenatide cannot protect against oxaliplatin-induced axonal degeneration. On the other hand, co-administration of exenatide repaired oxaliplatin-induced axonal degeneration on days 42 and 63. With respect to pain behavior, exenatide relieved oxaliplatin-induced mechanical allodynia. Therefore, these reparations of axonal degeneration by exenatide may partially contribute to the reversal of oxaliplatin-induced mechanical allodynia. The present results support the involvement of axonal degeneration in the incidence of mechanical allodynia.

Oxaliplatin has been reported to inhibit neurite outgrowth in cultured PC12 and rat DRG cells and decrease cell survival in DRG cells [13, 21]. In the present study, oxaliplatin shortened the length of neurites and decreased cell viability of cultured PC12 cells. We also found that exenatide reversed oxaliplatin-induced neurite shortening in cultured PC12 cells. However, exenatide had no effect on the oxaliplatin-induced decrease in cell viability. These results suggest that exenatide ameliorates neurodegeneration but not cell death induced by oxaliplatin. This hypothesis is supported by histological results from the tissue of rats’ co-administered oxaliplatin and exenatide. Thus, exenatide appears to facilitate recovery from oxaliplatin-induced nerve injury. Recently, exendin-4, a GLP-1 receptor agonist, has been reported to facilitate the nerve regeneration after the crush nerve injury [30]. GLP-1 receptor is localized on...
large and small peptidergic neurons of adult rat DRG cells [42], suggesting the involvement of GLP-1 receptor in both the large and small sensory fiber functions. Taken together, these findings indicate that GLP-1 receptor may be new target of therapeutic agents of the nerve regeneration after chemotherapy-induced neuropathy.

GLP-1 receptor agonists have been reported to exhibit neuroprotective effects via increasing cAMP [43], having anti-apoptotic properties [44], or activating the c-Jun N-terminal kinase (JNK)/extracellular signal-regulated kinase (ERK) signaling pathway [45]. Additionally, GLP-1 receptor agonists can promote NGF-mediated differentiation in PC12 cells [46]. Furthermore, NGF has been reported to protect DRG neurons from oxaliplatin by modulating stress-activated protein kinases/JNK and ERK1/2. [47]. Recently, exenin-4 has been reported to enhance neurite outgrowth and neuronal survival through the activation of phosphatidylinositol-3’-phosphate kinase (PI3K) signaling pathway in cultured adult rat DRG neurons and PC 12 cells [42]. These molecular mechanisms may be involved in the effect of exenatide on oxaliplatin-induced mechanical allodynia.

GLP-1 receptors are specifically expressed on microglial cells in the spinal dorsal horn, and profoundly upregulated after peripheral nerve injury [48]. In addition, intrathecal injection of GLP-1 receptor agonists GLP-1 and exenatide potently alleviate formalin-, peripheral nerve injury-, bone cancer-, and diabetes-induced hypersensitivity in rats [48]. The anti-hypersensitive effects of GLP-1 receptor agonists are completely inhibited by not only GLP-1 receptor antagonism and gene knockdown but also the microglial inhibitor minocycline [48]. In an animal model of Parkinson’s disease, exendin-4 protects dopaminergic neurons by inhibition of microglial activation [49]. These findings suggest that microglial is involved in the anti-hypersensitive and neuroprotective effects of GLP-1 receptor agonists. On the other hand, the activation of spinal astrocytes but not microglia has been reported to be involved in the oxaliplatin-induced neuropathic pain [15–17]. In the present study, our data showed that exenatide could not inhibit the incidence of oxaliplatin-induced mechanical allodynia. Taken together, glial function might not be involved in the effect of exenatide in this study.

The present results also show that exenatide had no effect on oxaliplatin-induced tumor cytotoxicity in C-26 cells. Moreover, extended-release exenatide had no effect on the anti-tumor effect of oxaliplatin in tumor cell-implanted mice. Therefore, it is unlikely that exenatide influences the anti-tumor effect of oxaliplatin.

**Conclusions**

The present results demonstrate for the first time that exenatide facilitates recovery from oxaliplatin-induced neuropathy without affecting anti-tumor activity. Some studies indicate that 10–20% of patients treated with oxaliplatin have type 2 diabetes [50, 51]. Therefore, exenatide may be useful for the treatment of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients with type 2 diabetes.

**Acknowledgments**

We appreciate the technical support from the Research Support Center, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

**Author Contributions**

Conceived and designed the experiments: NE SU RO TK. Performed the experiments: SF SU NO KM. Analyzed the data: SF SU. Wrote the paper: SF TK NE.
References

1. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005; 5 Suppl 1: S38–46. PMID: 15871765

2. Wilson RH, Lehty T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20: 1767–74. PMID: 11919233

3. Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys. 2006; 25: 263–76. PMID: 17197725

4. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008; 29: 1100–6. doi: 10.1016/j.neuro.2008.09.005 PMID: 18845186

5. Kawashiri T, Egashira N, Kuroke K, Tsutsumi K, Yamashita Y, Ushio S, et al. L type Ca2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain. 2012; 8: 7. doi: 10.1186/1744-8069-8-7 PMID: 22292988

6. Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain. 2012; 8: 55. doi: 10.1186/1744-8069-8-55 PMID: 22839205

7. Lolignier S, Bonnet C, Gaudioso C, Noël J, Ruel J, Amsalem M, et al. The Nav1.9 channel is a key determinant of cold pain sensation and cold allodynia. Cell Rep. 2015; 11: 1067–78. doi: 10.1016/j.celrep.2015.04.027 PMID: 25998919

8. Pasetto LM, D’Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006; 59: 159–68. PMID: 16806962

9. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005; 1: 249–58. PMID: 18360567

10. Land SR, Kopec JA, Cecchin RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25: 2205–11. PMID: 17470850

11. Cavaletti G, Tredici G, Petruccioli MG, Donè B, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001; 37: 2457–63. PMID: 11720843

12. Scuteri A, Galimberti A, Maggioni D, Ravasi M, Pasini S, Nicolini G, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009; 30: 312–9. doi: 10.1016/j.neuro.2009.01.003 PMID: 19428505

13. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006; 27: 992–1002. PMID: 16797073

14. Jameson SM, Liu J, Connor B, McKeage MJ. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol. 2005; 56: 391–9. PMID: 15887019

15. Yoon SY, Robinson CR, Zhang H, Dougherty PM. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J Pain. 2013; 14: 205–14. doi: 10.1016/j.jpain.2012.11.002 PMID: 23374942

16. Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014; 261: 22–33. doi: 10.1016/j.expneurol.2014.06.016 PMID: 24967684

17. Robinson CR, Zhang H, Dougherty PM. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience. 2014; 274: 308–17. doi: 10.1016/j.neuroscience.2014.05.051 PMID: 24905437

18. Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al. Antineuropathic profile of Na+-pamitoylthanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One. 2010; 10: e0128080. doi: 10.1371/journal.pone.0128080 PMID: 26039098

19. Di Cesare Mannelli L, Pacini A, Matera C, Zanardelli M, Mello T, De Amici M, et al. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology. 2014; 79: 37–48. doi: 10.1016/j.neuropharm.2013.10.034 PMID: 24225197

20. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000; 6: 1205–18. PMID: 10778943

21. Kawashiri T, Egashira N, Watanabe H, Ikekami Y, Hirakawa S, Mihara Y, et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain. 2011; 15: 344–50. doi: 10.1016/j.ejpain.2010.08.006 PMID: 20829082
22. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikeshue H, Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009; 147: 165–74. doi: 10.1016/j.pain.2009.09.003 PMID: 19782472

23. Mihara Y, Egashira N, Sada H, Kawashiri T, Ushio S, Yano T, et al. Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. Mol Pain. 2011; 7: 8. doi: 10.1186/1744-8069-7-8 PMID: 21247499

24. Shirahama M, Ushio S, Egashira N, Yamamoto S, Sada H, Masuguchi K, et al. Inhibition of Ca²⁺/calmodulin-dependent protein kinase II reverses oxaliplatin-induced mechanical allodynia in rats. Mol Pain. 2012; 8: 26. doi: 10.1186/1744-8069-8-26 PMID: 22510452

25. Tsutsumi K, Yamashita Y, Ushio S, Kawashiri T, Kaname T, Fujita S, et al. Oxaliplatin-induced hypoamyelination and reduced neuregulin 1 expression in the rat sciatic nerve. Neurosci Res. 2014; 80: 86–90. doi: 10.1016/j.neures.2014.02.004 PMID: 24530887

26. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32: 1941–67. doi: 10.1200/JCO.2013.54.0914 PMID: 24733808

27. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes. 2011; 60: 2397–406. doi: 10.2337/db10-1462 PMID: 21810596

28. Kan M, Guo G, Singh B, Singh V, Zochodne DW. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol. 2012; 71: 494–510. doi: 10.1097/NEN.0b013e1825860737 PMID: 22588388

29. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. 2011; 164: 1410–20. doi: 10.1111/j.1476-5381.2011.01272.x PMID: 21323903

30. Yamamoto K, Amako M, Yamamoto Y, Tsuchihara T, Nukada H, Yoshihara Y, et al. Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury. Biomed Res Int. 2013; 2013: 315848. doi: 10.1155/2013/315848 PMID: 23984340

31. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007; 203: 293–301. PMID: 17125767

32. Li H, Jia Z, Li G, Zhao X, Sun P, Wang J, et al. Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway. Int J Clin Exp Pathol. 2015; 8: 4837–43. PMID: 26911775

33. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003; 9: 1173–9. PMID: 12925848

34. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009; 106: 1285–90. doi: 10.1073/pnas.0806720106 PMID: 19164583

35. Belsham DD, Fick LJ, Dalvi PS, Centeno ML, Chalmers JA, Lee PK, et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEBJ. 2009; 23: 4256–65. doi: 10.1096/fj.09-133454 PMID: 19703933

36. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983; 16: 109–10. PMID: 6877845

37. Eakin K, Li Y, Chiang YH, Hoffert BJ, Rosenheim H, Greig NH, et al. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One. 2013; 8: e82016. doi: 10.1371/journal.pone.0082016 PMID: 24312624

38. Dalvi PS, Nazarians-Armavil A, Purser MJ, Belsham DD. Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology. 2012; 153: 2206–22. doi: 10.1210/en.2011-1795 PMID: 22334721

39. Fu Z, Kuang HY, Hao M, Gao XY, Liu Y, Shao N. Protection of exenatide for retinal ganglion cells with different glucose concentrations. Peptides. 2012; 37: 25–31. doi: 10.1016/j.peptides.2012.06.006 PMID: 22727809

40. Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, et al. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer. 2012; 48: 1407–13. doi: 10.1016/j.ejca.2011.08.009 PMID: 21907570
41. Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr). 2013; 35: 1621–36.

42. Tsukamoto M, Niimi N, Sango K, Takaku S, Kanazawa Y, Utsunomiya K. Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA. Histochem Cell Biol. 2015; 144: 249–59. doi: 10.1007/s00418-015-1333-3 PMID: 26026990

43. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2011; 31: 1696–705. doi: 10.1038/jcbfm.2011.51 PMID: 21487412

44. Velmurungan K, Bouchard R, Mahaffey G, Pugazhenth S. Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells. J Neurochem. 2012; 123: 919–31. doi: 10.1111/jnc.12036 PMID: 23020846

45. Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimers Dis. 2013; 37: 623–35. doi: 10.3233/JAD-130584 PMID: 24008687

46. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002; 300: 958–66. PMID: 11861804

47. Scuteri A, Galimberti A, Ravasi M, Pasini S, Donzelli E, Cavaletti G, et al. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sakp and ERK1/2. Neurosci Lett. 2010; 486: 141–5. doi: 10.1016/j.neulet.2010.09.028 PMID: 20850503

48. Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci. 2014; 34: 5322–34. doi: 10.1523/JNEUROSCI.4703-13.2014 PMID: 24719110

49. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol. 2009; 202: 431–9. doi: 10.1677/JOE-09-0132 PMID: 19570816

50. Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol. 2010; 21: 754–8. doi: 10.1093/annonc/mdp509 PMID: 19887466

51. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21: 1313–9. doi: 10.1007/s00520-012-1687-5 PMID: 23196819